

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 29D0538919	(X3) Date Survey Completed 04/25/2022
Name of Provider or Supplier Comprehensive Cancer Centers Of Nevada-Twain	Street Address, City, State 3730 S Eastern Ave, Las Vegas, NV	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	<p>This Statement of Deficiencies was created as a result of an on-site CLIA recertification survey conducted at your facility on April 25, 2022. The findings and conclusions of any investigation by the Division of Public and Behavioral Health shall not be construed as prohibiting any criminal or civil investigations, actions or other claims for relief that may be available to any party under applicable federal, state, or local laws.</p>
D5215	<p>EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(b)(2)</p> <p>The laboratory must verify the accuracy of any analyte, specialty or subspecialty assigned a proficiency testing score that does not reflect laboratory test performance (that is, when the proficiency testing program does not obtain the agreement required for scoring as specified in subpart I of this part, or the laboratory receives a zero score for nonparticipation, or late return or results).</p> <p>This STANDARD is not met as evidenced by: Based on a review of the 2020 and 2021 American Proficiency Institute (API) Hematology/Coagulation Proficiency Testing (PT) results, a review of the 2020 and 2021 College of American Pathologists (CAP) Electrophoresis Proficiency Testing (PT), and an interview with the Technical Consultant, the laboratory failed to review the participant summary to evaluate the laboratory results submitted to the proficiency testing programs for ungraded results and educational challenges. Findings include: 1. A review of the 2020 API Hematology/Coagulation test event one revealed that there was no documentation of a review of the data summary for the ungraded result for the Educational Blood Cell Identification specimen ECI-01. 2. A review of the 2020 API Hematology/Coagulation test event two revealed that there was no documentation of a review of the data summary for the ungraded result for Blood Cell Identification specimen BCI-09, and for the Educational Blood Cell Identification ECI-06. 3. A review of the 2020 API Hematology/Coagulation test event three revealed that there</p>

was no documentation of a review of the data summary for the ungraded result for the Blood Cell Identification specimen BCI-11, and for the Educational Cell Identification specimen ECI-13. 4. A review of the 2021 API Hematology /Coagulation test event one revealed that there was no documentation of a review of the data summary for the Educational Blood Cell Identification for specimen ECI-03. 5. A review of the 2021 API Hematology/Coagulation test event two revealed that there was no documentation of a review of the data summary for the ungraded result for Blood Cell Identification specimen BCI-07, and for the ungraded Platelet Estimate result for specimen DIF-02. 6. A review of the 2021 API Hematology/Coagulation test event three revealed that there was no documentation of a review of the data summary for the ungraded result for the Educational Blood Cell Identification specimen ECI-15, and for the ungraded Platelet Estimate result for specimen DIF-03. 7. A review of the CAP 2020 Electrophoresis test event A revealed that there was no documentation of a review of the participant summary for the educational challenge for specimens SPE-01 and SPE-02 for the following tests: albumin electrophoresis (% and g/dl), alpha 1 globulin (% and g/dl), alpha 2 globulin (% and g/dl), beta globulin (% and g/dl), and total gamma globulin (% and g/dl). 8. A review of the CAP 2020 Electrophoresis test event B revealed that there was no documentation of a review of the participant summary for the educational challenge for specimens SPE-01 and SPE-02 for the following tests: albumin electrophoresis (% and g/dl), alpha 1 globulin (% and g/dl), alpha 2 globulin (% and g/dl), beta globulin (% and g/dl), and total gamma globulin (% and g/dl). 9. A review of the CAP 2021 Electrophoresis test event A revealed that there was no documentation of a review of the participant summary for the educational challenge for specimens SPE-01 and SPE-02 for the following tests: albumin electrophoresis (% and g/dl), alpha 1 globulin (% and g/dl), alpha 2 globulin (% and g/dl), beta globulin (% and g/dl), and total gamma globulin (% and g/dl). 10. A review of the CAP 2021 Electrophoresis test event B revealed that there was no documentation of a review of the participant summary for the educational challenge for specimens SPE-01 and SPE-02 for the following tests: albumin electrophoresis (% and g/dl), alpha 1 globulin (% and g/dl), alpha 2 globulin (% and g/dl), beta globulin (% and g/dl), and total gamma globulin (% and g/dl). 11. The findings were confirmed during an interview with the Technical Consultant on April 25, 2022 at approximately 11:30 AM. The laboratory performs approximately 1,520,000 chemistry tests and 206,982 hematology tests annually.